Merck Reports Strong Phase 3 Results for Oral PCSK9 Inhibitor
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 02 2026
0mins
Should l Buy MRK?
Source: Yahoo Finance
- Clinical Trial Success: On March 30, 2026, Merck announced positive results from the CORALreef AddOn trial, demonstrating that the oral PCSK9 inhibitor enlicitide reduced LDL-C levels by 64.6% when combined with statins, indicating its potential in cardiovascular disease treatment.
- High Patient Success Rate: The trial showed that 78.2% of patients achieved the LDL-C target of less than 55 mg/dL, highlighting enlicitide's effectiveness and good patient adherence, which may lay the groundwork for future market promotion.
- Strategic Acquisition: On March 25, 2026, Merck acquired clinical-stage oncology company Terns Pharmaceuticals for $6.7 billion, aiming to expand its hematology portfolio and strengthen its position in oncology, reflecting its commitment to diversification strategies.
- Stable Safety Profile: Enlicitide's safety profile remained consistent with previous trials, with no serious adverse events reported, providing confidence for its future market launch and potentially attracting more investor interest in its market performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to rise
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 119.070
Low
95.00
Averages
119.53
High
139.00
Current: 119.070
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Merck & Co Inc: FDA Establishes PDUFA Action Date for August 17, 2026
- Merck & Co. Announcement: Merck & Co. has set a target action date of August 17, 2026, for its product under review by the FDA.
- FDA Review Process: The announcement indicates that the FDA is currently evaluating Merck's submission, with a decision expected by the specified date.
See More
FDA Approves Priority Review for Keytruda® and Keytruda Qlex™ in Combination with Padcev® for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin
FDA Grants Priority Review: The FDA has granted priority review for two drugs, Keytruda® (pembrolizumab) and Keytruda QLEX™ (pembrolizumab and berahyaluronidase), aimed at treating muscle-invasive bladder cancer.
Indication for Eligible Patients: These treatments are specifically for patients with muscle-invasive bladder cancer who are eligible for cisplatin-based chemotherapy.
See More
FDA Grants Priority Review for Pfizer and Astellas' Padcev with Keytruda for Bladder Cancer
- FDA Priority Review: Pfizer and Astellas announced that the FDA has granted priority review for their marketing application of Padcev in combination with Merck's Keytruda, marking a significant advancement in bladder cancer treatment.
- Indication Expansion: The application aims to expand the use of Padcev with Keytruda to all muscle-invasive bladder cancer patients, not just those ineligible for cisplatin chemotherapy, which is expected to significantly broaden the potential market.
- Clinical Trial Success: This application is based on data from the Phase 3 EV-304 trial, which successfully met its primary endpoint of event-free survival, providing strong support for FDA approval of the therapy.
- Target Action Date: The FDA has set August 17, 2026, as the target action date for the supplemental Biologics License Application, and if approved, it will offer new treatment options for patients, further solidifying Pfizer and Astellas' market position in oncology.
See More
KEYTRUDA and Padcev Combination Shows Significant Survival Benefits in Bladder Cancer
- Clinical Trial Results: The Phase 3 KEYNOTE-B15 trial demonstrated that the combination of KEYTRUDA and Padcev significantly improved event-free survival and overall survival in muscle-invasive bladder cancer (MIBC) patients, indicating its potential efficacy.
- FDA Priority Review: The U.S. FDA has granted priority review for the supplemental Biologics License Applications (sBLA) for KEYTRUDA and KEYTRUDA QLEX, which, if approved, would be the first perioperative treatment for all MIBC patients, potentially changing the standard of care.
- Patient Recruitment: The KEYNOTE-B15 trial enrolled 808 patients to compare the perioperative treatment of KEYTRUDA combined with Padcev against traditional chemotherapy, aiming to assess its efficacy and safety before and after surgery.
- Future Outlook: If approved, the indications for KEYTRUDA and KEYTRUDA QLEX will expand to all MIBC patients, further solidifying Merck's leadership in oncology immunotherapy and providing new treatment options for patients.
See More
Recursion Pharmaceuticals Expands Partnership with Citeline to Enhance AI Drug Discovery
- Partnership Expansion: Recursion Pharmaceuticals has expanded its partnership with Citeline to integrate real-world data capabilities into its AI-driven drug discovery platform, thereby enhancing the efficiency of clinical trial design and development decisions.
- Drug Development Potential: Although Recursion has no market products yet, it boasts a substantial pipeline of potential drug products, including partnered programs with major pharmaceutical companies like Roche, Merck, Bayer, and Sanofi, indicating broad applicability in cancer and rare disease treatments.
- Strong Financial Position: By the end of 2025, Recursion had received over $500 million in milestone payments from partnered programs, with future potential payments exceeding $300 million, providing robust financial support for ongoing operations.
- Market Strategy: Recursion is considering an Amazon Prime-like subscription sales model for its drugs upon market entry, which could ensure revenue stability and attract more pharmaceutical companies to participate in promoting its drug offerings.
See More
Health Care Stocks Rise 1.4% on NYSE
- Strong Performance in Health Care: The NYSE Health Care Index rose 1.4% late Friday afternoon, indicating a rebound in investor confidence towards the healthcare sector, likely driven by an overall improvement in market sentiment.
- Signs of Market Recovery: The rise in healthcare stocks suggests that investors may be reassessing the growth potential of the healthcare industry while seeking safe-haven assets amid increasing economic uncertainty.
- Increased Investor Attention: The uptick in healthcare stocks could attract more investor interest, particularly as the healthcare sector is viewed as a relatively stable investment choice in the current economic climate, potentially leading to increased capital inflows.
- Optimistic Industry Outlook: The upward trend in the healthcare sector may reflect market optimism regarding future medical innovations and policy support, further driving stock price increases for related companies.
See More
Merck & Co Inc: FDA Establishes PDUFA Action Date for August 17, 2026
- Merck & Co. Announcement: Merck & Co. has set a target action date of August 17, 2026, for its product under review by the FDA.
- FDA Review Process: The announcement indicates that the FDA is currently evaluating Merck's submission, with a decision expected by the specified date.
See More
FDA Approves Priority Review for Keytruda® and Keytruda Qlex™ in Combination with Padcev® for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin
FDA Grants Priority Review: The FDA has granted priority review for two drugs, Keytruda® (pembrolizumab) and Keytruda QLEX™ (pembrolizumab and berahyaluronidase), aimed at treating muscle-invasive bladder cancer.
Indication for Eligible Patients: These treatments are specifically for patients with muscle-invasive bladder cancer who are eligible for cisplatin-based chemotherapy.
See More
FDA Grants Priority Review for Pfizer and Astellas' Padcev with Keytruda for Bladder Cancer
- FDA Priority Review: Pfizer and Astellas announced that the FDA has granted priority review for their marketing application of Padcev in combination with Merck's Keytruda, marking a significant advancement in bladder cancer treatment.
- Indication Expansion: The application aims to expand the use of Padcev with Keytruda to all muscle-invasive bladder cancer patients, not just those ineligible for cisplatin chemotherapy, which is expected to significantly broaden the potential market.
- Clinical Trial Success: This application is based on data from the Phase 3 EV-304 trial, which successfully met its primary endpoint of event-free survival, providing strong support for FDA approval of the therapy.
- Target Action Date: The FDA has set August 17, 2026, as the target action date for the supplemental Biologics License Application, and if approved, it will offer new treatment options for patients, further solidifying Pfizer and Astellas' market position in oncology.
See More
KEYTRUDA and Padcev Combination Shows Significant Survival Benefits in Bladder Cancer
- Clinical Trial Results: The Phase 3 KEYNOTE-B15 trial demonstrated that the combination of KEYTRUDA and Padcev significantly improved event-free survival and overall survival in muscle-invasive bladder cancer (MIBC) patients, indicating its potential efficacy.
- FDA Priority Review: The U.S. FDA has granted priority review for the supplemental Biologics License Applications (sBLA) for KEYTRUDA and KEYTRUDA QLEX, which, if approved, would be the first perioperative treatment for all MIBC patients, potentially changing the standard of care.
- Patient Recruitment: The KEYNOTE-B15 trial enrolled 808 patients to compare the perioperative treatment of KEYTRUDA combined with Padcev against traditional chemotherapy, aiming to assess its efficacy and safety before and after surgery.
- Future Outlook: If approved, the indications for KEYTRUDA and KEYTRUDA QLEX will expand to all MIBC patients, further solidifying Merck's leadership in oncology immunotherapy and providing new treatment options for patients.
See More
Recursion Pharmaceuticals Expands Partnership with Citeline to Enhance AI Drug Discovery
- Partnership Expansion: Recursion Pharmaceuticals has expanded its partnership with Citeline to integrate real-world data capabilities into its AI-driven drug discovery platform, thereby enhancing the efficiency of clinical trial design and development decisions.
- Drug Development Potential: Although Recursion has no market products yet, it boasts a substantial pipeline of potential drug products, including partnered programs with major pharmaceutical companies like Roche, Merck, Bayer, and Sanofi, indicating broad applicability in cancer and rare disease treatments.
- Strong Financial Position: By the end of 2025, Recursion had received over $500 million in milestone payments from partnered programs, with future potential payments exceeding $300 million, providing robust financial support for ongoing operations.
- Market Strategy: Recursion is considering an Amazon Prime-like subscription sales model for its drugs upon market entry, which could ensure revenue stability and attract more pharmaceutical companies to participate in promoting its drug offerings.
See More
Health Care Stocks Rise 1.4% on NYSE
- Strong Performance in Health Care: The NYSE Health Care Index rose 1.4% late Friday afternoon, indicating a rebound in investor confidence towards the healthcare sector, likely driven by an overall improvement in market sentiment.
- Signs of Market Recovery: The rise in healthcare stocks suggests that investors may be reassessing the growth potential of the healthcare industry while seeking safe-haven assets amid increasing economic uncertainty.
- Increased Investor Attention: The uptick in healthcare stocks could attract more investor interest, particularly as the healthcare sector is viewed as a relatively stable investment choice in the current economic climate, potentially leading to increased capital inflows.
- Optimistic Industry Outlook: The upward trend in the healthcare sector may reflect market optimism regarding future medical innovations and policy support, further driving stock price increases for related companies.
See More
